Army awards Baltimore's Profectus BioSciences $8.5M for Ebola vaccine work
Oct 22, 2014, 2:51pm EDT
Baltimore biopharmaceutical company Profectus BioSciences Inc. has received a three-year, $8.5 million grant from the U.S. Army for work on an Ebola vaccine.
Profectus will share the grant with the Galveston National Laboratory at the University of Texas Medical Branch at Galveston. The grant is Profectus' second in recent days. The company also announced a $5.8 million grant from the Biomedical Advanced Research and Development Authority (BARDA) to conduct safety studies of the company's VesiculoVax, a potential Ebola vaccine.
The BARDA funding will also allow Profectus to begin manufacturing the vaccine for Phase I clinical studies. The one-year contract can be extended to up to 13 months and $8.6 million.
